[Androgen therapy of incurable breast neoplasms. Controlled clinical study: nandrolone-testololactone-drostanolone].
In 91 patients with advanced breast cancer testololactone, drostanolone, and nandrolone were compared in a controlled clinical trial. Remissions were registered after 4 weeks and after another 12 week period; during this second interval the patients received an additional treatment with cyclophosphamide. There was no difference in the effectivity between the three drugs. Remission rate was in average after 4 weeks 24% and after 16 weeks 46%.
D000732:Androstanols / Q000627:therapeutic use; D000736:Androstenes / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D009277:Nandrolone / Q000627:therapeutic use; D013738:Testolactone / Q000031:analogs & derivatives; D045165:Testosterone Congeners / Q000627:therapeutic use*; D014770:Virilism / Q000139:chemically induced
D000732:Androstanols; D000736:Androstenes; D045165:Testosterone Congeners; C018155:testololactone; D013738:Testolactone; D009277:Nandrolone; D003520:Cyclophosphamide
Zur Androgentherapie des inkurablen Mammakarzinoms Kontrollierter klinischer Versuch: Nandrolon-Testololakton-Drostanolon.